22 results about "Pemetrexed" patented technology

The invention provides a pharmaceutical composition for treating non-small cell lung cancer and a use method, and belongs to the technical field of tumor immunotherapy. The invention formulates a non-small cell lung cancer weak chemotherapy and anti-vascular immunity triple treatment scheme based on the combination of a low-dose chemotherapy drug pemetrexed, an immune checkpoint inhibitor and an anti-angiogenesis drug. According to the scheme, low-dose pemetrexed is combined with the anti-angiogenesis medicine and the immune checkpoint inhibitor for use, the optimal synergistic effect can be achieved, meanwhile, the renal toxicity and the myelosuppression risk are remarkably reduced, and the pemetrexed medicine composition is expected to become one of the optimal choices for driving gene negative and PD-L1 positive expression non-squamous NSCLC patients, and has a wide application prospect. The device is suitable for old people or patients with poor physical states; especially for patients with negative driver genes and positive PD-L1 expression, the traditional treatment blank is filled, and clinical data shows that survival benefits are remarkable.

Described herein are methods of treating a MTAP-null lung cancer in a patient comprising administering to the patient a PRMT5 inhibitor and an anti-PD1 antibody, optionally in combination with carboplatin and either paclitaxel or pemetrexed. Further described herein are methods of treating a MTAP-null cancer in a patient also suffering from brain metastases comprising administering to the patient a PRMT5 inhibitor.

The invention discloses a pemetrexed-containing sustained-release implant and application thereof. The sustained-release implant is prepared from the following substances in percentage by weight: 5 to 60 percent of pemetrexed or pemetrexed sodium salt and 40 to 95 percent of sustained-release auxiliary materials. The preparation method has the beneficial effects that the degradable polymer auxiliary material is used as a dispersion matrix, the stability of medicine quality is ensured, the release period is prolonged, the release behavior is improved, no obvious sudden release or delayed release exists in in-vitro release, continuous production can be realized by adopting a solid-solid mixed hot-melt extrusion method, the production efficiency of the implant is remarkably improved, the production cost is reduced, and the preparation method is suitable for industrial production. The industrialization is easy; no solvent participates in the preparation process, no solvent residue exists, and the safety is high; the medicine is dispersed uniformly and released controllably; the preparation is safe and reliable in quality and more beneficial to clinical application.

Methods for treating non-small cell lung cancer (NSCLC) include the administration of a combination of 2,2'-dithio-bis-ethane sulfonate, carboplatin, and pemetrexed. The methods are based on tumor mutational burden (TMB) assessment, with specific treatment regimens tailored to the mutational profile of the tumor. When a low tumor mutational burden is detected in a tumor sample, the combination therapy of 2,2'-dithio-bis-ethane sulfonate, carboplatin, and pemetrexed is administered, offering enhanced therapeutic efficacy.

The invention relates to application of O-GlcNAc modified OPG in preparation of drugs for enhancing drug sensitivity of tumor cells. The amino acid sequence of the OPG is shown as SEQ ID NO.1, and O-GlcNAc modification exists at the site S151 of the OPG. According to the invention, the O-GlcNAc modification obviously enhances the stability and activity of the OPG protein and the correlation between the O-GlcNAc modified OPG and the malignant progression of tumors. The method focuses on an O-GlcNAc modification related protein spectrum and identifies and defines a new substrate modified by O-GlcNAc; the invention discloses that O-GlcNAc modified OPG is mediated by membrane protein EHD1 to promote malignant progression of tumors in a manner of promoting a cell cycle axis, and clarifies a novel tumor treatment means, and drug resistance of lung adenocarcinoma tumor cells to carboplatin and pemetrexed can be reversed by breaking an O-GlcNAc modified OPG axis, so that the curative effect of chemical treatment is improved.

This invention discloses an ODC1 gene biomarker for prognostic assessment of lung adenocarcinoma treated with pemetrexed / cisplatin combined chemotherapy and its application. Firstly, it proposes the application of the ODC1 gene in the preparation of reagents for prognostic assessment of lung adenocarcinoma treated with pemetrexed / cisplatin combined chemotherapy. The ENSEMBLE number for the ODC1 gene is ENST00000234111.9. Secondly, it proposes a kit for assessing the sensitivity of lung adenocarcinoma to pemetrexed / cisplatin combined chemotherapy, which includes reagents for detecting ODC1 expression levels. Based on cell experiments and clinical data validation, this invention reveals that the ODC1 gene plays a crucial mediating role in ferroptosis, and its expression level is correlated with the sensitivity of cells to ferroptosis inducers and combined chemotherapy treatment. As a biomarker to help predict the sensitivity or tolerance of lung adenocarcinoma patients to chemotherapy, it has significant clinical application value.

The present disclosure relates to the treatment of solid cancers, such as breast cancer, colon cancer, and lung cancer (particularly non-small cell lung cancer (NSCLC)), in human subjects using anti-PD-1 antibodies as monotherapy or as combination therapy with, for example, chemotherapy and / or surgery. The treatments provided may be a combination of tiralizumab and chemotherapy prior to surgery, using different doses of tiralizumab in an auxiliary stage after surgery. Administration regimens may include administration of 200 mg of an anti-PD-1 antibody (e.g., tiralizumab) (e.g., every three weeks) followed by tumor resection, followed by administration of 400 mg of the anti-PD-1 antibody (e.g., every six weeks). Furthermore, the chemotherapy may be platinum-based (e.g., carboplatin and / or cis-platinum), and may further include pemetrexed (e.g., for non-squamous cancer) or paclitaxel (e.g., for squamous cancer).

The application discloses a kind of pemetrexed liposome and its preparation method and application, it is made of including 2mg / mL~20mg / mL pemetrexed or its pharmaceutically acceptable salt, 2.2mg / mL~12mg / mL cholesterols, 6.81mg / mL~108mg / mL neutral lipid, 12mg / mL~98mg / mL cationic lipid and 0.12mg / mL~2.12mg / mL PEG-lipid.The pemetrexed liposome of the application can significantly improve the enrichment of pemetrexed drug in tumor site, thereby enhancing drug treatment effect, reducing dosing dose, reducing the toxic side effects of drug on normal tissue.And it has good stability, no obvious change in storage process nature, particle size, zeta potential and encapsulation efficiency.

This invention relates to the field of biomedical technology and provides the application of pemetrexed in the preparation of anticoccidial drugs. This invention discloses a novel application of pemetrexed in the preparation of anticoccidial drugs, verifying that the compound has clear anti-parasitic activity in vitro, significantly improves chick survival rate, weight gain, reduces oocyst expulsion, and alleviates cecal lesions in vivo, with an anticoccidial index (ACI) rating of moderate efficacy. Furthermore, it exhibits low cytotoxicity and good safety, providing a new candidate and application direction for anticoccidial drugs.

The application relates to application of a combined use of bruceine D and pemetrexed in the preparation of a drug for treating lung cancer, and belongs to the technical field of biological medicine. The combined use of bruceine D (BD) and pemetrexed (PEM) for treating lung cancer shows a synergistic effect, can more effectively inhibit tumor growth than single drugs, more significantly inhibit lung cancer cell activity and proliferation capacity, reduce lung cancer cell colony formation capacity, and inhibit tumor volume increase and terminal tumor weight increase. In a pemetrexed-resistant lung cancer model, the single drug BD can play a significant role in inhibiting tumors, inhibit pemetrexed-resistant lung cancer cell activity, reduce pemetrexed-resistant lung cancer cell colony formation capacity, and show independent anti-tumor activity; it is shown that BD has a significant therapeutic effect on pemetrexed-resistant lung cancer, and provides a new intervention means for pemetrexed-resistant lung cancer.

The present invention relates to an inhalable tumor-microenvironment-targeted drug delivery system for treating lung cancer. Specifically, the present invention provides a lipid-polymer hybrid nanoparticle comprising: a poly(lactic-co-glycolic acid) (PLGA) polymer core that encapsulates a first therapeutic agent such as paclitaxel (PTX); and a lipid shell functionalized with pemetrexed (PEM) that performs a dual function as both an anticancer agent and a target ligand. The nanoparticles are directly delivered to the lungs through inhalation, simultaneously target folate receptor alpha (FR-α) of lung cancer cells and folate receptor beta (FR-β) of immunosuppressive tumor-associated macrophages (M2-TAMs) through a PEM ligand, and can repolarize M2-TAMs into an immunoactive M1 phenotype, while exhibiting a direct cancer cell killing effect by PTX and PEM.

The specification relates to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for use in the treatment of EGFR TKI-naïve patients with locally-advanced or metastatic EGFR mutation-positive non-small cell lung cancer (NSCLC), wherein the EGFR TKI is administered in combination with pemetrexed and platinum chemotherapy.

The descriptive memorandum refers to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for use in the treatment of previously EGFR TKI-naïve patients with metastatic or locally advanced EGFR mutation-positive non-small cell lung cancer (NSCLC), wherein the EGFR TKI is administered in combination with platinum-based chemotherapy and pemetrexed.

To provide a pemetrexed formulation comprising a non-aqueous solvent that remains stable for at least about 48 hours after dilution when stored at 2 °C to 8 °C.SOLUTION: In certain embodiments, the invention is directed to a pharmaceutical composition comprising pemetrexed and a non-aqueous medium present at a concentration of less than 0. 30ml / mL, wherein upon dilution with a pharmaceutically acceptable diluent to an initial dosage concentration of pemetrexed, the composition comprises at least 90% of the initial dosage concentration of pemetrexed after storage for at least 24 hours at a temperature of 2 °C to 8 °C.SELECTED DRAWING: None

The present invention refers to an intravenous infusion dosage form comprising a composition containing pemetrexed or its pharmaceutically acceptable salt, an osmagent and an aquous vehicle. The composition is present in a flexible infusion container containing an inert gas in the headspace. Additionally, a second container may be present surrounding the flexible infusion container.

Provided herein are methods of treating a cancer comprising a KRAS G12C mutation in a subject in need thereof, the methods comprising administering to the subject an amount of sotoprasib, carboplatin, and pemetrexed effective to treat the cancer.

Disclosed herein are methods of using amivantamab in combination with carboplatin and pemetrexed for the treatment of non-small cell lung cancer (NSCLC).

Provided herein is a method for treating cancer involving a KRAS G12C mutation in a subject requiring treatment, the method comprising administering to the subject an effective dose of sotrasib, carboplatin, and pemetrexed to treat the cancer.

The present invention relates to a method of treating non-small cell lung cancer (NSCLC) which harbors a KRAS G12C mutation, wherein the method comprises the administration of a therapeutically effective amount of KRAS G12C inhibitor 1-{6-[(4M)-4-(5-Chloro-6-methyl-5 1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one (Compound A), or a pharmaceutically acceptable salt, solvate or hydrate thereof, a therapeutically effective amount of pembrolizumab, a therapeutically effective amount of pemetrexed and a therapeutically effective amount of platinum therapy; in particular the present invention relates to a method of treating NSCLC wherein the NSCLC expresses at least 1% PD-L1 according to the tumor proportion score (TPS), more particularly wherein the NSCLC expresses less than 50% PD-L1 according to the tumor proportion score (TPS), more particularly wherein the NSCLC expresses PD-L1 1- 49% according to the tumor proportion score (TPS), even more particularly wherein the NSCLC expresses <1% PD-L1 according to the tumor proportion score (TPS).

The disclosure relates generally to alpha polyglutamated pemetrexed, formulations containing liposomes filled with alpha polyglutamated pemetrexed, methods of making the alpha polyglutamated pemetrexed and liposome containing formulations, and methods of using polyglutamated alpha polyglutamated pemetrexed and liposome containing formulations to treat hyperproliferative disorders (e.g., cancer) and disorders of the immune system (e.g., an autoimmune disease such as rheumatoid arthritis).

The present application relates to a kind of pemetrexed crystal form alpha, preparation method and its application, the crystal form alpha prepared at room temperature has no or almost no hygroscopicity;Pemetrexed crystal form alpha is stable, and the pemetrexed tablet prepared as pharmaceutical active ingredient has good storage stability and dissolution batch uniformity, even in high humidity environment, impurities are not obviously increased, drug distribution is uniform, release behavior is stable, dissolution performance is excellent, has stable drug efficacy.